Merck drops telcagepant migraine drug


Telcagepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist for the treatment of migraine, will not be developed further, according to a statement issued as part of Merck’s second-quarter earnings statement and reported by Dow Jones (,000-jobsreports-2q-net-gain).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page